BAXTER INTERNATIONAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.43 USD | -0.73% |
|
-2.96% | -8.35% |
| May. 13 | Baxter International's Clinolipid Injection Approved for Expanded Use in US | MT |
| May. 10 | TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 | MT |
Presenter SpeechJayson Bedford (Analysts)And welcome to the 44th Annual Raymond James Institut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows:
- medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.);
- kidney dialysis drugs and equipment (30.1%);
- systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.;
- other (20.1%).
Export accounts for 52.7% of net sales.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.43
USD
Average target price
46.47
USD
Spread / Average Target
+31.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.35% | 18.05B | |
| -4.82% | 182B | |
| +1.38% | 111B | |
| -2.82% | 68.48B | |
| +0.69% | 49.69B | |
| +8.54% | 44.46B | |
| +2.04% | 40.67B | |
| +20.50% | 31.22B | |
| +1.72% | 26.09B | |
| +15.23% | 25.32B |
- Stock Market
- Equities
- BAX Stock
- News Baxter International Inc.
- Transcript : Baxter International Inc. Presents at Raymond James 44th Annual Institutional Investors Conference, Mar-06-2023 01